PR
Precipio, Inc.
PRPO · NASDAQ
$26.46 +2.12% (+$0.55)
1M -14.97%
Market Cap $47.2M
P/E Ratio -
Div. Yield -
ROE 8.49%
Bulios Fair Price
$16.75
36.7% downside
Current Price
$26.46
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PRPO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
25 /100
Expensive EV/EBITDA 192.77x
P/FCF 47.88x
P/S 1.72x
Growth
79 /100
Growing Rev. growth 36.71%
Book val. growth 3.69%
EPS growth N/A
Profitability
26 /100
Weak Gross margin 43.69%
FCF margin 3.59%
Net margin 4.42%
Quality
15 /100
Poor ROIC 8.43%
Asset turnover 1.29x
ROE 8.49%
Debt
93 /100
Low Debt/Equity 0.23x
Net debt/EBITDA 1.06x
Current ratio 1.77x
Stability
42 /100
Moderate Beta 1.33x
Profitable years 0
Rev. volatility 29.94%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRPO
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ilan Danieli
Employees
61
Headquarters
New Haven
Upcoming events
16 NOV
Earnings
Upcoming earnings report